Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Acerus Pharmaceuticals Corporation (T:ASP)

Business Focus: Pharmaceuticals (NEC)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEDAR
Company Contact
Address: 7025 Langer Drive, Suite 205
Tel: N/A
IR: See website
Key People
Ian O. Ihnatowycz
Chairman of the Board
Edward Joseph Gudaitis
President, Chief Executive Officer, Director
Robert M. Motz
Chief Financial Officer
Gavin Damstra
Senior Vice President - International Commercial
Kevin Hickey
Senior Vice President - US Commercial
Philippe Savard
Vice President, General Counsel, Corporate Secretary
Christopher Sorli
Chief Medical Officer
Business Overview
Acerus Pharmaceuticals Corporation is a Canada-based specialty pharmaceutical company. The Company is focused on the commercialization and development of prescription products with a primary focus in the field of men's health. Its product, Natesto, is a testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. It has two product pipelines, such as avanafil, which is a chemical entity PDE5 inhibitor for the treatment of erectile dysfunction and Lidbree, is a short acting lidocaine formulation delivered through a device into the vaginal mucosal tissue. It also has product rights to Tefina, a clinical stage product aimed at addressing an unmet need for women with female sexual dysfunction. Its non-prescription product includes Elegant, which is a vaginal moisturizer. Its primary market is the United States where it commercializes its product with their contract commercial provider Syneos Health (Syneos).
Financial Overview
For the nine months ended 30 September 2021, AcerusPharmaceuticals Corporation revenues increased 70% to$1.4M. Net loss increased 43% to $24.8M. Revenues reflectUnited states segment increase of 57% to $982K. Higher netloss reflects Change in fair value of derivative finandecrease of 74% to $41K (income), Interest income decreaseof 89% to $7K (income). Basic Earnings per Share excludingExtraordinary Items remained flat at -$0.02.
Employees: 10 as of Dec 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $52.69M as of Sep 30, 2021
Annual revenue (TTM): $2.07M as of Sep 30, 2021
EBITDA (TTM): -$29.00M as of Sep 30, 2021
Net annual income (TTM): -$39.91M as of Sep 30, 2021
Free cash flow (TTM): -$26.70M as of Sep 30, 2021
Net Debt Last Fiscal Year: $18.45M as of Sep 30, 2021
Shares outstanding: 1,537,588,081 as of Sep 30, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization